Tomografía por emisión de positrones (PET) en el manejo del paciente con cáncer de mama

Cabrera, 2000, Diagnóstico de malignidad y estadificación, 139 Warburg, 1931, 129 Hiraki, 1988, Growth factors rapidly induce expression of the glucose transporter gene, J Biol Chem, 27, 13655, 10.1016/S0021-9258(18)68291-2 Farina, 1968, Metabolic regulation and enzyme alterations in the Morris hepatomas, Cancer Res, 28, 1897 Delbeke, 1999, Oncological applications of FDG PET imaging, J Nucl Med, 40, 1706 Schiedhauer, 1996, Qualitative (18F) FDG positron emission tomography in primary breast cancer: Clinical relevance and practicability, Eur J Nucl Med, 23, 618, 10.1007/BF00834522 Silverstein, 1994, Axillary lymph node dissection for T1a breast carcinoma: is it indicated?, Cancer, 73, 664, 10.1002/1097-0142(19940201)73:3<664::AID-CNCR2820730326>3.0.CO;2-S Avril, 1996, Assessment of axillary lymph node involvement in breast cancer patients with positron emission romography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-Glucose, J Natl Cancer Inst, 88, 1204, 10.1093/jnci/88.17.1204 Flanagan, 1998, PET in breast cancer, Semm Nucl Med., 28, 290, 10.1016/S0001-2998(98)80034-2 Harris, 1993, Cancer of the breast, 1264 Richter, 2000, Oncología II: Evaluación terapéutica, 161 Mortimer, 1996, Clinical correlation of FDG and FES PET imaging with estrogen receptor and response to systemic therapy, Clin Cancer Res, 2, 933 Wahl, 1993, Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation, J Clin Oncol, 11, 2101, 10.1200/JCO.1993.11.11.2101 Bender, 1997, Value of 18-fluorodeoxyglucose positron emission tomography in the staging of recurrent breast carcinoma, Anticancer Res, 17, 1687 Moon, 1998, Accuracy of whole-body fluorine-18-FDG PET for detection of recurrent or metastatic breast carcinoma, J Nucl Med., 39, 431